Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a…
- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023…
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of…
Topline Results Expected Third Quarter 2023 Long COVID Afflicts Approximately 19% of Patients Following COVID-191, and is Expected to be…
KNOXVILLE, TN, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on…
Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena’s…
BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and…
Composite qEEG measure showed change from placebo after first dose of 5 mg Effect in the composite qEEG measured through…
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors…
CHAPEL HILL, NC / ACCESSWIRE / August 5, 2023 / Dr. Brad Burton, a renowned expert in pharmacy education and…